Table 3.
Comparison between pre-clinical/clinical inhibitors and pomegranate/pomegranate compounds having PI3K/Akt/mTOR inhibitory potential.
| Inhibitor name |
Cancer |
Results |
References |
|---|---|---|---|
| Pre-clinical/clinical PI3K/Akt/mTOR inhibitors | |||
| AZD5363 | Breast cancer | Inhibited cell proliferation, induced apoptotic conditions, and Inhibited tumorigenesis | [[244], [245], [246]] |
| Prostate cancer | |||
| Gastric cancer | |||
| CCI-779 | Renal carcinoma | [[247], [248], [249]] | |
| Breast cancer | |||
| GDC0980 | Advanced solid tumors | [250] | |
| BKM120 | Breast cancer | [251] | |
| CAL-101 | Leukemia | [252,253] | |
| B cell malignancies | |||
| XL-147 | Advanced solid tumors | [254,255] | |
| Advanced endometrial carcinoma | |||
| PF-04691502 | Advanced solid tumors | [256] | |
| Endometrial cancer | |||
| Pomegranate PI3K/Akt/mTOR inhibitors | |||
| Pomegranate juice | Colon cancer | Modulated inflammatory cell signaling | [47] |
| Pomegranate total tannin extract | |||
| Punicalagin | |||
| Pomegranate juice | Prostate Cancer | Inhibited cell proliferation | [243] |
| Pomegranate peel extract | |||
| Pomegranate fruit extract | Lung cancer | Inhibited tumorigenesis | [43] |
| Pomegranate polyphenolics | Breast cancer | Reduced inflammation | [257] |
| Induced cytotoxicity in cancer cells | |||
| Pomegranate juice | Colon cancer | Decreased cell proliferation | [42] |
| Urolithin A | Pancreatic Cancer | Reduced cell proliferation and induced cell apoptosis | [258] |